Clinical trials: Cardiac Ischemia
Coronary Heart Disease, Hypercholesterolemia
Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)
This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines.
- Conditions
- Coronary Heart Disease, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT00723723
- Testing
- Statin
- Volunteers
- 555 people
- Sponsor
- Organon and Co
Coronary Artery Disease, Left Ventricular Dysfunction
DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation
This trial is a prospective, multi-center, randomized study of patients with coronary artery disease (CAD) and mild to moderate left ventricular (LV) dysfunction.
- Conditions
- Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
- Trial name
- DETERMINE (NCT00487279)
- Testing
- Defibrillator, Control
- Where
- 56 sites in United States
- Volunteers
- 81 people
- Sponsor
- Abbott Medical Devices
Angina, Coronary Occlusion
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
The objectives of the PMS are to observe the frequency, type, and degree of device deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to collect information on evaluation of the efficacy and…
- Conditions
- Angina, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Stenosis
- Trial name
- NCT01721096
- Testing
- XIENCE PRIME - Long Length (LL), XIENCE PRIME - Core Size
- Where
- Japan
- Volunteers
- 536 people
- Sponsor
- Abbott Medical Devices
Class IV Angina
The PEARL 8.0 Post-Approval Study
This is a prospective single arm study of the Cardiogenesis PEARL 8.0 Handpiece Delivery System. The purpose of this study is to demonstrate that the 30 day mortality rate among patients who are treated with this device is less…
- Trial name
- NCT01845103
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Ischemia, Coronary Artery Disease
A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions
One of the purpose of this study is to assess the preliminary safety and feasibility,and to provide related information and evidence for the design of the further pivotal randomized control trial.the other purpose is to assess…
- Trial name
- CREDIT (NCT01909869)
- Testing
- EXCEL-Ⅱ
- Where
- China
- Volunteers
- 45 people
- Sponsor
- JW Medical Systems Ltd
Atrial Fibrillation, Oral Anticoagulation
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO).
- Conditions
- Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
- Trial name
- INTERCEPT (NCT05723926)
- Testing
- Vine Filter
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Javelin Medical
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome
FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes
The objective of this study is to evaluate the safety and efficacy of A 002 when added to high dose atorvastatin in subjects with an acute coronary syndrome (ACS)
- Trial name
- FRANCIS-ACS (NCT00743925)
- Testing
- Varespladib Methyl (A-002)
- Where
- 44 sites in Georgia, Russia and 1 more
- Volunteers
- 625 people
- Sponsor
- Anthera Pharmaceuticals
Coronary Artery Disease, Angioplasty, Transluminal, Percutaneous Coronary
European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent
The main objective of this study is to assess the safety and effectiveness of the TiN-coated MAR-Tyn stent in maintaining minimum lumen diameter in de novo native coronary artery lesions as compared to an uncoated control…
- Conditions
- Coronary Artery Disease, Angioplasty, Transluminal, Percutaneous Coronary, Stents
- Trial name
- MARTIN (NCT00637104)
- Testing
- Mar-Tyn TiN coated Co-Cr Numen stent implant, Vision Co-Cr stent implant
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 160 people
- Sponsor
- International Biomedical Systems S.p.A.
Coronary Artery Disease, Cerebrovascular Disease
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
The objective of this study is to evaluate an antibiotic therapy called Rifalazil to determine its effect on hardening of the carotid arteries.
- Conditions
- Coronary Artery Disease, Cerebrovascular Disease, Peripheral Vascular Disease
- Trial name
- NCT00385385
- Testing
- Rifalazil
- Where
- 6 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- ActivBiotics
Foramen Ovale, Patent
The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness
The primary objective of this study is to demonstrate the safety and efficacy of the PFX Closure System when utilized for patent foramen ovale (PFO) in patients suffering from cryptogenic stroke (undetermined cause of stroke)…
- Trial name
- NCT00196040
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Cierra
Cardiogenic Shock, Extracorporeal Membrane Oxygenation
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation, ECLS, VA ECMO
- Trial name
- PulseSE (NCT05106491)
- Testing
- Synchronized Cardiac Support with the icor kit
- Where
- 2 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Xenios AG
Coronary Artery Disease
XIENCE Skypoint Large Vessel Post Approval Study
SPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent…
- Trial name
- SPIRIT XLV PAS (NCT05423379)
- Testing
- XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 102 people
- Sponsor
- Abbott Medical Devices
Acute Coronary Syndrome
OPTIMIZE IDE for the Treatment of ACS
Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery…
- Trial name
- OPTIMIZE (NCT03190473)
- Testing
- DES
- Where
- 72 sites in United States, Japan and 1 more
- Volunteers
- 1,630 people
- Sponsor
- Svelte Medical Systems, Inc.
Hypercholesterolemia
A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)
The purpose of this study was to evaluate the long-term safety and tolerability of ezetimibe 10 mg once daily co-administered with atorvastatin 10 to 80 mg daily for up to 12 consecutive months in participants with heterozygous…
- Trial name
- NCT03882996
- Testing
- Ezetimibe, Atorvastatin
- Volunteers
- 432 people
- Sponsor
- Organon and Co
Coronary Artery Disease, Cardiovascular Diseases
A Novel Non-Invasive Acoustic Diagnostic for the Diagnosis of Coronary Artery Disease The CAD-det Validation Study
The purpose of the study is to collect acoustic, ECG, and clinical data from consenting participants, so that AusculSciences can perform analysis on the sounds produced by the heart and determine the accuracy of the CAD-det…
- Conditions
- Coronary Artery Disease, Cardiovascular Diseases, Atherosclerosis, Coronary Occlusion
- Trial name
- NCT04562142
- Testing
- CAD-det
- Where
- 2 sites in Canada
- Volunteers
- 395 people
- Sponsor
- AusculSciences Canada Inc.
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Heart Failure
Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
Evaluate the efficacy and safety of Jia Shen Tablets in patients with Chronic Heart Failure.
- Trial name
- NCT06669169
- Testing
- Low dose Jia Shen Tablet, High dose Jia Shen Tablet
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Ischemic Heart Disease
Study to Evaluate the Safety and Effectiveness of the Biosensors Microcatheter in Coronary Chronic Total Occlusions (CTO) - BIOMICS
Biosensors, the Sponsor would like to determine if the Biosensors Microcatheter is safe and effective in treating patients with CTO by assessing a composite of in-hospital cardiac death or myocardial infarction and device success…
- Trial name
- BIOMICS (NCT04966273)
- Testing
- Microcatheter
- Where
- 9 sites in United Kingdom
- Volunteers
- 101 people
- Sponsor
- Biosensors Europe SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.